Jonathan Zalevsky - Dec 13, 2024 Form 4 Insider Report for NEKTAR THERAPEUTICS (NKTR)

Role
Chief R&D Officer
Signature
Mark A. Wilson, Attorney-in-Fact
Stock symbol
NKTR
Transactions as of
Dec 13, 2024
Transactions value $
$0
Form type
4
Date filed
12/17/2024, 08:55 PM
Previous filing
Nov 20, 2024
Next filing
Dec 20, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NKTR Common Stock Award $0 +135K +55.55% $0.00 378K Dec 13, 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NKTR Stock Option Award $0 +270K $0.00 270K Dec 13, 2024 Common Stock 270K $4.91 Direct F3, F4
transaction NKTR Stock Option Award $0 +375K $0.00 375K Dec 13, 2024 Common Stock 375K $1.01 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Common stock was acquired pursuant to a grant of restricted stock units ("RSU"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of Common Stock of the Issuer. These RSUs were granted on August 15, 2022 under the Issuer's Amended and Restated 2017 Performance Incentive Plan (the "2017 Plan") and at the time of their grant were subject to both performance-based and time-based vesting requirements. The time-based vesting is on a quarterly pro-rata basis over a period of three years from the date of grant.
F2 The Organization and Compensation Committee of the Board of Directors of the Issuer ("Compensation Committee") determined on November 18, 2024 that the performance-based vesting requirement for these RSUs was satisfied and these RSUs vested on December 13, 2024 (subject to remaining time-based vesting requirements).
F3 These stock options were granted on August 15, 2022 under the 2017 Plan and at the time of their grant were subject to both performance-based and time-based vesting requirements. The time-based vesting is on a monthly pro-rata basis over a period of three years from the date of grant.
F4 The Compensation Committee determined on November 18, 2024 that the performance-based vesting requirement for these stock options was satisfied and these stock options vested on December 13, 2024 (subject to remaining time-based vesting requirements).
F5 Stock options vest over four years from the date of grant, (December 13, 2024) in equal monthly installments based on continued service.